Analysis of HSPCs from BM and spleens of mice (n = 12 per group) from the experiment shown inFigure 3 . (A) Total BM cellularity of treated mice (number of cells per 2 femurs, 2 tibias plus pelvis). (B) Percentages of early (CD71+ Ter119+ FSC^high), mid (CD71+ Ter119+ FSC^low) and late (CD71− Ter119+ FSC^low) erythroid precursors among all Ter119+ cells in each treatment arm (C) MCV of reticulocytes after 6 weeks of treatment. Individual values of each mouse are also plotted. (D) Top: frequencies of indicated subpopulations in BM, represented as percentage of total BM: HSCs (lin− ckit+ Sca1+ CD150+ CD48−), MPP (lin− ckit+ Sca1+, excluding HSCs), common myeloid progenitor (lin− ckit+ Sca1− CD34+ CD16−), pre-MegE (lin− ckit+ Sca1− CD41− CD16− CD105− CD150+), megakaryocyte progenitors (MkP) (lin− ckit+ Sca1− CD41+ CD150+), and CFU-E (lin− ckit+ Sca1− CD41− CD16− CD105+ CD150−). Bottom: VF;GFP chimerism (% GFP+ cells) in each population. (E) Top: frequencies of indicated subpopulations in the spleen, represented as percentage of total spleen cells. Cell types were identified as in panel B. Bottom: VF;GFP chimerism (% of GFP+ cells) in each population in the spleen. The plots represent the mean ± SEM. 1-way ANOVA was performed, followed by Fisher LSD test for statistical comparisons of each treatment group with the vehicle. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001.